|Min SIP Amount||₹500|
|NAV||₹136.73 (30 Oct 2020)|
|Fund Started||01 Jan 2013|
|Fund Size||₹586 Cr|
|Dr. Reddy's Laboratories Ltd.||Healthcare||Equity||11.0%|
|Sun Pharmaceutical Inds. Ltd.||Healthcare||Equity||10.6%|
|Divi's Laboratories Ltd.||Healthcare||Equity||7.7%|
|Ipca Laboratories Ltd.||Healthcare||Equity||6.1%|
|Cadila Healthcare Ltd.||Healthcare||Equity||5.7%|
|Aurobindo Pharma Ltd.||Healthcare||Equity||4.2%|
|Eris Lifesciences Ltd||Healthcare||Equity||4.1%|
|Laurus Labs Ltd.||Healthcare||Equity||3.9%|
UTI Healthcare Fund Direct Growth is a Equity Mutual Fund Scheme launched by UTI Mutual Fund. This scheme was made available to investors on 01 Jan 2013. V Srivatsa, Ritesh Rathod is the Current Fund Manager of UTI Healthcare Fund Direct Growth fund.The fund currently has an Asset Under Management(AUM) of ₹586 Cr and the Latest NAV as of 30 Oct 2020 is ₹136.73.
The UTI Healthcare Fund Direct Growth is rated High risk. Minimum SIP Investment is set to 500. Minimum Lumpsum Investment is 5000. Exit load of 1% if redeemed less than 1 year
The scheme seeks to generate long term capital appreciation by investing predominantly in equity and equity related securities of companies/institutions engaged in the Healthcare Services Sector.
Returns are taxed at 15%, if you redeem before one year. After 1 year, you are required to pay LTCG tax of 10% on returns of Rs 1 lakh+ in a financial year.